|Bid||0.00 x 3200|
|Ask||52.43 x 1800|
|Day's Range||51.63 - 52.50|
|52 Week Range||41.23 - 52.83|
|Beta (3Y Monthly)||0.76|
|PE Ratio (TTM)||21.29|
|Forward Dividend & Yield||1.25 (2.40%)|
|1y Target Est||53.90|
Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.
The U.S. Food and Drug Administration on Monday approved Novo Nordisk's Victoza, a liraglutide injection, for the treatment of young patients 10 years or older with Type 2 diabetes. Although Victoza has been FDA-approved to treat adults with Type 2 diabetes since 2010, it is the only non-insulin drug approved for children other than metformin, which was approved for pediatric use in 2000. "Victoza has now been shown to improve blood sugar control in pediatric patients with Type 2 diabetes. The expanded indication provides an additional treatment option at a time when an increasing number of children are being diagnosed with this disease," said Lisa Yanoff, acting director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. Type 2 diabetes occurs when the pancreas is unable to make enough insulin to keep blood sugar at normal levels. It's the most common form of diabetes, normally occurring in patients 45 years or older. However, in the past two decades, its prevalence among younger patients has dramatically risen. More than 5,000 new cases of Type 2 diabetes are now diagnosed each year in the U.S. among people younger than age 20, according to the Centers for Disease and Control and Prevention. Shares of Novo Nordisk have gained 10.8% so far this year, while the SPDR S&P Pharmaceuticals ETF has gained 3%. The Dow Jones Industrial Average has gained 11.8% and the S&P 500 has gained 15.3%.
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Amgen Inc., Biogen Inc., Gilead Inc. and Novo Nordisk A/S all have “very high” capacity for M&A activity, Moody’s Investors Service said in a report published Thursday.
Shares of pharmaceutical companies Johnson & Johnson and Novo Nordisk popped Wednesday on bullish expectations for their diabetes treatments after the American Diabetes Association meeting.
Since Novo Nordisk A/S (CPH:NOVO B) released its earnings in March 2019, analyst forecasts seem fairly subdued, as a...
Pharmaceutical company Novo Nordisk said Tuesday its experimental diabetes treatment proved safe in patients with heart disease. It could rival drugs from Lilly, AstraZeneca and Sanofi.
An experimental oral form of a Novo Nordisk drug for type 2 diabetes posed no greater risk of serious heart problems or death than a placebo in patients at high risk for such complications, according to data from a large study presented on Tuesday. Patients with type 2 diabetics and either heart disease or at high risk for heart problems who received the drug semaglutide in pill form had a combined rate of heart attack, stroke or heart-related death of 3.8% compared with 4.8% for placebo, successfully demonstrating non-inferiortiy.
European stocks finished higher for a third day on Tuesday, as German shares caught up with a global stock rally after a holiday on easing trade tensions, while fresh stimulus for China's slowing economy boosted the basic resources sector. The pan-European STOXX 600 index closed at its highest level since May 17, with miners, auto stocks and chemical companies tacking on biggest gains after reports that Beijing was opening the door to more spending by local governments.
Eli Lilly announced positive results in a long-term trial of its diabetes drug Trulicity, but that doesn’t seem to have been enough for Wall Street.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 2) Alcon AG (NYSE: ALC ) Dr.Reddy's Laboratories Ltd (NYSE: ...